Age of 18 and over, male or female;
Patients with histologically confirmed advanced (stage IV) gastric cancer, NSCLC, breast cancer or ovarian cancer, who choose monotherapy of oral vascular targeting drug (apatinib) due to intolerability or inappropriateness of other therapies;
Presence of measurable lesions (=10mm on spiral CT scan) subject to RECIST 1.1;
Blood pressured controlled at 150/100 mHg following drug administration;
An ECOG PS score of between 0 and 1;
A life expectancy of at least 3 months;
Subjects who volunteer to participate in this study and have signed the Informed Consent Form (ICF), with good compliance with treatment and follow-up.

NCT03475589_inc_T1
Person
Age
NCT03475589_inc_T2
Value
18 and over
NCT03475589_inc_T3
Person
male
NCT03475589_inc_T4
Person
female
NCT03475589_inc_T5
Qualifier
histologically confirmed
NCT03475589_inc_T6
Procedure
histologically
NCT03475589_inc_T7
Qualifier
advanced
NCT03475589_inc_T8
Qualifier
stage IV
NCT03475589_inc_T9
Condition
gastric cancer
NCT03475589_inc_T10
Condition
NSCLC
NCT03475589_inc_T11
Condition
breast cancer
NCT03475589_inc_T12
Condition
ovarian cancer
NCT03475589_inc_T13
Procedure
monotherapy
NCT03475589_inc_T14
Drug
oral vascular targeting drug
NCT03475589_inc_T15
Drug
apatinib
NCT03475589_inc_T17
Scope
gastric cancer, NSCLC, breast cancer or ovarian cancer
NCT03475589_inc_T18
Condition
measurable lesions
NCT03475589_inc_T19
Value
=10mm
NCT03475589_inc_T20
Procedure
spiral CT scan
NCT03475589_inc_T21
Qualifier
RECIST 1.1
NCT03475589_inc_T22
Measurement
Blood pressured
NCT03475589_inc_T23
Qualifier
controlled
NCT03475589_inc_T24
Value
150/100 mHg
NCT03475589_inc_T25
Measurement
ECOG PS
NCT03475589_inc_T26
Value
between 0 and 1
NCT03475589_inc_T27
Observation
life expectancy
NCT03475589_inc_T28
Value
at least 3 months